ReviewBMC nephrology2025
Autosomal dominant focal segmental glomerulosclerosis by INF2 p.Arg218Trp and p.Ser186Pro mutations: three case reports and literature review.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFocal segmental glomerulosclerosis(FSGS) is a histologic lesion of podocyte injury with diverse etiologies including mutations in the inverted formin-2 gene(INF2), which belongs to the formin family and regulates actin cytoskeleton-dependent cellular processes. CASE PRESENTATION: We report two cases of INF2 p.Arg218Trp and one case of p.Ser186Pro, all exhibiting an autosomal dominant(AD) inheritance pattern. The clinical presentations of the two patients with INF2 p.Arg218Trp varied widely. One patient, diagnosed with proteinuria in adolescence, maintained normal renal function, while the other experienced a youthful onset followed by rapid progression to end-stage renal disease (ESRD) and required hemodialysis treatment. The patient with p.Ser186Pro also had an early onset, with renal biopsy revealing progression from minimal change disease (MCD) to FSGS, leading to ESRD and necessitating hemodialysis treatment.
conclusionsThese cases add to the clinical spectrum associated with INF2-related FSGS and underscore the importance of genetic evaluation in patients with early-onset or familial kidney disease. They show considerable intrafamilial and interfamilial variability in penetrance and expressivity, highlighting the complexity of genotype-phenotype correlations. Genetic screening and family counseling remain essential in suspected hereditary FSGS. Further studies are warranted to clarify the molecular mechanisms and guide management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.